Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Postponed PAFSC 2nd Committee Meeting Set for November 11
October 31, 2016
- MID-NET Working Group Discusses Access Fee Calculations
October 28, 2016
- Long-Listed Drug Use by Welfare Recipients Should Require Copay: MOF
October 28, 2016
- Panel Negative about Singling Out OTC-Switched Rx for Health Coverage Talks, Calls for Broader Discussions
October 27, 2016
- Shiozaki Does Not Rule Out Price Cut of Over 25% for Opdivo
October 27, 2016
- MHLW Alerts on Risk of Fulminant Type 1 Diabetes for Keytruda
October 25, 2016
- Pharma Groups Tender Requests to LDP on FY2017 Budget, Tax Reform
October 24, 2016
- Govt Panel Members Call for Drastic Drug Pricing Reform, Annual Revision
October 24, 2016
- Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
October 24, 2016
- New Govt Panel Holds 1st Meeting for Healthcare, Long-Term Care
October 21, 2016
- MHLW Panel to Discuss Health Coverage of Ethical Drugs with OTC Versions on Oct. 26
October 21, 2016
- Oct. 27 MHLW Panel Meeting Postponed Due to Lack of Quorum
October 21, 2016
- Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
October 21, 2016
- Heads of Medicines Regulatory Agencies to Hold Summit in Kyoto Next October
October 20, 2016
- Shiozaki Asks for Early Enactment of Clinical Research Bill
October 20, 2016
- MHLW Task Force Calls for Consolidation in Vaccines, Blood Products Industries; “Fundamental to National Security”: Minister
October 20, 2016
- LDP Taskforce Agrees to Squeeze Social Security Budget by 140 Billion Yen
October 19, 2016
- Opdivo Ordered to Add Immune Thrombocytopenic Purpura in ADR List
October 19, 2016
- Concomitant Use of Warfarin and Florid Contraindicated: MHLW
October 19, 2016
- Health Minister Nudges Kaketsuken on Biz Handover to Astellas
October 19, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…